Largazole: From discovery to broad-spectrum therapy
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
The cyclic depsipeptide largazole from a cyanobacterium of the genus Symploca is a marine natural product with a novel chemical scaffold and potently inhibits class I histone deacetylases (HDACs). Largazole possesses highly differential growth-inhibitory activity, preferentially targeting transformed over non-transformed cells. The intriguing structure and biological activity of largazole have attracted strong interest from the synthetic chemistry community to establish synthetic routes to largazole and to investigate its potential as a cancer therapeutic. This Highlight surveys recent advances in this area with a focus on the discovery, synthesis, target identification, structure-activity relationships, HDAC8-largazole thiol crystal structure, and biological studies, including in vivo anticancer and osteogenic activities.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in cellular contexts, the IC50 values of thiol HDACi decrease significantly, due to reduction/hydrolysis of prodrugs. Whereas in vitro experiments that lack reductants or hydrolases show increased IC50 values of such inhibitors [85, 86].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [86]
In the citing paper
“Similarly, largazole (Figure 15A), a thioester, is recognized as a thioesterase substrate in cells and is hydrolyzed to release a free thiol as a ZBG (Figure 15B) [86, 87].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [86]
In the citing paper
“Cyanobacteria are known to be a rich source of highly bioactive natural products32–35, and in particular, protease inhibitors from numerous chemical classes36–41.”
From Native metabolomics identifies the rivulariapeptolide family of protease inhibitors (2022) · cites this paper as [32]
Citations
Cites
(2002) · PubMed · Cited by 732
Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer
Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2004) · The Prostate · doi:10.1002/pros.20022 · Cited by 509
Marine Natural Products: A New Wave of Drugs?
Montaser, R., & Luesch, H. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.118 · Cited by 437
Self-citationTaori, K., Paul, V. J., & Luesch, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja7110064 · Cited by 428
Self-citationRole of the Ras-Association Domain Family 1 Tumor Suppressor Gene in Human Cancers
Agathanggelou, A., Cooper, W. N., & Latif, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4088 · Cited by 388
Luesch, H., Moore, R. E., Paul, V. J., Mooberry, S. L., & Corbett, T. H. (2001) · Journal of Natural Products · doi:10.1021/np010049y · Cited by 378
Self-citationBiologically active secondary metabolites from marine cyanobacteria
Nunnery, J. K., Mevers, E., & Gerwick, W. H. (2010) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2010.09.019 · Cited by 265
PTEN Level in Tumor Suppression: How Much Is Too Little?
Carracedo, A., Alimonti, A., & Pandolfi, P. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2488 · Cited by 246
Kawai, H., Li, H., Avraham, S., Jiang, S., & Avraham, H. K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11403 · Cited by 226
Total Synthesis and Molecular Target of Largazole, a Histone Deacetylase Inhibitor
Ying, Y., Taori, K., Kim, H., Hong, J., & Luesch, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8013727 · Cited by 222
Self-citation
Research works printed but not linked: 6
- Behar, 2010, Newsweek, 156, 40
- Furumai, 2002, Cancer Res., 62, 4916
- Ren, 2008, Synlett, 2379
- Numajiri, 2008, Synlett, 2483
- Wang, 2009, Synthesis, 2873
- Jeon, 2010, Int. J. Oncol., 37, 419
Cited by
Items 101–186 of 186
The epigenetic landscape of rheumatoid arthritis: Pathogenesis and drug therapeutic potentials
Huang, C., Liang, Y., Li, Y., Quan, W., Ouyang, L., & Zhang, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.08.022 · Cited by 21
“8A) 224 .”
Gao, S., Ge, Y., Bent, A. F., Schwarz‐Linek, U., & Naismith, J. H. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00835 · Cited by 15
Cyanobacteria as a Source for Novel Anti-Leukemic Compounds
Humisto, A., Herfindal, L., Jokela, J., Karkman, A., Bjørnstad, R., Choudhury, R. R., & Sivonen, K. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201016666150826121124 · Cited by 14
Dewaker, V., Srivastava, P. N., Verma, S. K., & Prabhakar, Y. S. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1598497 · Cited by 14
“This generated considerable interest in this scaffold leading to different synthetic analogues in order to expand its scope in anticancer drug development (Chen et al., 2014; Hong & Luesch, 2012; Kim et al., 2017; Pilon et al., 2015; Ying et al., 2008).”
Zhang, B., Liu, J., Gao, D., Yu, X., Wang, J., & Lei, X. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111672 · Cited by 14
Marine Peptide Secondary Metabolites
Banaigs, B., Bonnard, I., Witczak, A., & Inguimbert, N. (2014) · Wiley eBooks · doi:10.1002/9783527681501.ch13 · Cited by 18
Shen, Z., Huo, Y., Qi, X., & Wu, X. (2023) · Organic Letters · doi:10.1021/acs.orglett.3c01400 · Cited by 13
Liu, L., Herfindal, L., Jokela, J., Shishido, T. K., Wahlsten, M., Døskeland, S. O., & Sivonen, K. (2014) · Marine Drugs · doi:10.3390/md12042036 · Cited by 16
“Marine cyanobacteria are considered a good source for novel bioactivities, and many potent bioactive compounds and drug leads have been isolated and identified, such as apratoxin A, bisebromoamide, coibamide and largazole [20–23].”
Decroos, C., & Christianson, D. W. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00536 · Cited by 12
Problems and Prospects of Applications of Cyanobacteria (Review)
Polyak, Y. M., & Сухаревич, В. И. (2023) · Inland Water Biology · doi:10.1134/s1995082923010121 · Cited by 13
Zhang, B., Shan, G., Zheng, Y., Yu, X., Ruan, Z., Li, Y., & Lei, X. (2019) · Marine Drugs · doi:10.3390/md17060333 · Cited by 12
Hitora, Y., & Tsukamoto, S. (2025) · Natural Product Reports · doi:10.1039/d5np00004a · Cited by 12
An epigenetic small molecule screen to target abnormal nuclear morphology in human cells
Atanasova, K. R., Chakraborty, S., Ratnayake, R., Khare, K. D., Luesch, H., & Lele, T. P. (2022) · Molecular Biology of the Cell · doi:10.1091/mbc.e21-10-0528 · Cited by 14
“…were among the 14 hits (apicidin and pyroxamide), for further validation we also included FK228, an FDA-approved class I HDAC inhibitor, and our marine-derived preclinical class I HDAC inhibitor largazole (Hong and Luesch, 2012; Al-Awadhi et al., 2020) to probe for potential HDAC class selectivity.”
Self-citationMarine Cyanobacteria: A Prolific Source of Bioactive Natural Products as Drug Leads
Tan, L. T. (2013) · Wiley eBooks · doi:10.1002/9783527665259.ch05 · Cited by 12
Atanasova, K. R., Perkins, C. M., Ratnayake, R., Jiang, J., Chen, Q.-Y., Schmittgen, T. D., & Luesch, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1335246 · Cited by 13
“The ADM reversal assay screen was performed in duplicate using the Cayman ESL on Cre mouse organoids.”
InfluentialSelf-citationCyanobacteria as Valuable Tool in Biotechnology
Śliżewska, A., & Żymańczyk–Duda, E. (2021) · Catalysts · doi:10.3390/catal11111259 · Cited by 13
“The initial screening tests have shown its effectiveness against inter alia colorectal cancer, breast cancer, lung cancer, prostate cancer, or human malignant melanoma, and interestingly, the mechanism of action is different depending on the type of cancer cells [83].”
Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials
Trinidad-Calderón, P. A., Varela-Chinchilla, C. D., & García‐Lara, S. (2023) · Molecules · doi:10.3390/molecules28020670 · Cited by 10
“This macrocyclic depsipeptide, containing a thiazole unit linked to a 4-Me-thiazoline, a non-modified L-valine residue, and a thioester responsible for its mechanism of action [199,200], has exhibited a wide range of in vitro and in vivo biological activities such as antitumor, anti-osteogenic, and antifibrotic [201].”
Cubillos, C. F., Aguilar, P., Moreira, D., Bertolino, P., Iniesto, M., Dorador, C., & López‐García, P. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00072-24 · Cited by 14
“The latter genus groups cyanobacteria produc ing highly cytotoxic compounds (76), which might perhaps facilitate its colonization across samples.”
Wang, G., Wang, J., Yin, P., Xu, K., Wang, Y., Shi, F., Gao, J., & Fu, X. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27388 · Cited by 9
“The delay of tumor growth was shown in different mouse xenograft models for the alternative therapy of SCD1 enzyme (Hong & Luesch, 2012).”
Luo, D., & Luesch, H. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00473 · Cited by 9
Self-citationFenteany, G., Sharma, G., Gaur, P., Borics, A., Wéber, E., Kiss, E., & Haracska, L. (2022) · iScience · doi:10.1016/j.isci.2022.104053 · Cited by 9
“…Uba1 inhibitors (Fenteany et al., 2019, 2020; Sekizawa et al., 2002; Tsukamoto et al., 2005; Yang et al., 2007; Lu et al., 2010; Xu et al., 2010b; Hong and Luesch, 2012; Ungermannova et al., 2012a, 2012b, 2013; Yamanokuchi et al., 2012; An and Statsyuk, 2013, 2015; Hyer et al., 2018; Hann et…”
Parker, P. D., Ge, Y., & Pierce, J. G. (2017) · Tetrahedron Letters · doi:10.1016/j.tetlet.2017.12.043 · Cited by 8
Chen, X., Zhou, Z. P., Li, Z., & Xu, X. (2019) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426507.2019.1661413 · Cited by 8
The Impact of Fluorination on the Design of Histone Deacetylase Inhibitors
Anh, D. T., Nam, N., Kircher, B., & Baecker, D. (2023) · Molecules · doi:10.3390/molecules28041973 · Cited by 8
“It effectively inhibits the HDACs of class I [62].”
Histone Deacetylase Inhibitors in Cancer Prevention and Therapy
Movafagh, S., & Munson, A. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812494-9.00004-4 · Cited by 12
Synthesis and Antiproliferative Activity of Nitric Oxide-Donor Largazole Prodrugs
Borgini, M., Zamperini, C., Poggialini, F., Ferrante, L., Summa, V., Botta, M., & Fabio, R. D. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00643 · Cited by 8
Microalgae: A Treasure Trove of Anticancer Nutraceuticals and Promising Therapeutic Mechanisms
Masoumi, S., Zokaei, M., Ahmadvand, A., Ghalamkarpour, N., Asadimanesh, N., Azarimatin, A., Fattah, K., Payandeh, Z., Rostami, M., Farjami, A., et al. (2025) · Advanced Biomedical Research · doi:10.4103/abr.abr_101_24 · Cited by 9
“[114] The anticancer efficacy of the algal samples isolated from the Bulgarian strain Coelastrella sp. BGV (Bulgarian strain), under the fluorescence microscopic analysis against HeLa tumor cells, mediates apoptosis induction.”
(2023) · Microbial Bioactives · doi:10.25163/microbbioacts.617330 · Cited by 9
HDAC Inhibitors and Other Histone Modifying Natural Products as Emerging Anticancer Agents
Salvador, L. A., & Luesch, H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4654-5_4 · Cited by 8
Self-citationLiang, Z., Lv, K., Zhou, S., Zhu, C., & Bao, X. (2021) · Organic Chemistry Frontiers · doi:10.1039/d1qo01076j · Cited by 7
Biological Activity and Stability of Aeruginosamides from Cyanobacteria
Cegłowska, M., Kwiecień, P., Szubert, K., Brzuzan, P., Florczyk, M., Edwards, C., Kosakowska, A., & Mazur‐Marzec, H. (2022) · Marine Drugs · doi:10.3390/md20020093 · Cited by 9
“Largazole, another bioactive compound produced by Symploca, is explored as an anticancer drug that acts by inhibiting class I histone deacetylases (HDACs) [7].”
Cyanobacterial anticancer compounds in clinical use: Lessons from the dolastatins and cryptophycins
Aesöy, R., & Herfindal, L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821491-6.00003-x · Cited by 9
Senhorinho, G. N. A., Lannér, C., & Scott, J. A. (2018) · Phycological Research · doi:10.1111/pre.12362 · Cited by 7
“Interestingly, studies have shown that microalgal extracts can contain compounds with growth inhibitory activity towards malignant cells and have been investigated as potential anticancer therapies (Hong & Luesch 2012).”
Current Prospects and Clinical Status of Microalgae Derived Chemotherapeutics
Joshi, V., & Bharadvaja, N. (2023) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-023-00384-9 · Cited by 8
“Largazole possesses highly differential growth-inhibitory activity, preferentially targeting transformed over non-transformed cells (Hong and Luesch 2012).”
Ecological and environmental services of microalgae
Sharma, A., & Arya, S. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91869-5.00007-7 · Cited by 8
Xu, H., Roberts, L. R., Chou, S., Pierce, B. S., Narayanan, A., & Jones, L. H. (2017) · MedChemComm · doi:10.1039/c6md00633g · Cited by 7
Non-peptidic natural products as ubiquitin-proteasome inhibitors
Sengupta, S., & Mehta, G. (2019) · Tetrahedron · doi:10.1016/j.tet.2018.12.012 · Cited by 7
Dewaker, V., & Prabhakar, Y. S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266250924230920042845 · Cited by 7
Macrocyclic Inhibitors of Zinc-dependent Histone Deacetylases (HDACs)
Ganesan, A. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782623113-00109 · Cited by 7
Chemical peptide macrolactonization via intramolecular S‐to‐S‐to‐O acyl transfer
Nagano, M., Huang, Y., Obexer, R., & Suga, H. (2022) · Peptide Science · doi:10.1002/pep2.24259 · Cited by 5
Létévé, M., Gonzalez, C., Moroy, G., Martinez, A., Jeanblanc, J., Legastelois, R., Naassïla, M., Sápi, J., & Bourguet, E. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.08.016 · Cited by 5
Promising Marine Molecules in Pharmacology
Bourguet‐Kondracki, M., & Kornprobst, J. (2014) · Wiley eBooks · doi:10.1002/9783527681501.ch11 · Cited by 7
Ai, H., Lü, W., & Wu, X. (2021) · Angewandte Chemie · doi:10.1002/ange.202106079 · Cited by 4
Thiazole conjugated amino acid derivatives as potent cytotoxic agents
Le, H. T., Nguyen, N. T. H., Hong, Q. V., Qian, Z., Huê, B. T. B., Huynh, L. N., Hnin, S. Y. Y., Htoo, Z. P., Le, A. P. T., Tran, Q. D., et al. (2025) · RSC Advances · doi:10.1039/d5ra04425a · Cited by 4
Metabolic pathways for production of anticancer compounds in cyanobacteria
Amin, N., & Kannaujiya, V. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821710-8.00006-0 · Cited by 2
Bioactive compounds and pigments from cyanobacteria: Applications in the pharmaceutical industry
Sitther, V., Wyatt, L., Jones, C., & Yalcin, Y. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91202-0.00009-9 · Cited by 6
Sanchez, G. J., Liu, Z., Hunter, S., Xu, Q., Westfall, J., Wheeler, G. E., Toomey, C. M., Taatjes, D. J., Allen, M. A., Dowell, R. D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.29.635612 · Cited by 3
“Largazole treatment induces cell cycle arrest and apoptosis in various cancer cell lines in vitro and tumor suppression in vivo 8 .”
Harnessing engineered cyanobacteria for next-generation therapeutics
Bhardwaj, A., & Mishra, A. K. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04790-0 · Cited by 2
Venkatraman, A., Moovendhan, M., Kumar, C., Ramesh, S., Albert, A., Panchatcharam, S., Yacoob, S. A. M., Bhuvana, P., Yogananth, N., & Kuppusamy, S. G. (2022) · Biomass Conversion and Biorefinery · doi:10.1007/s13399-022-02786-6 · Cited by 2
“Many examples of MM metabolites are fucoxanthin [12], cryptophycin [13], borophycin [14], cucarin-A [15], calothrixins A and B [16], scytonemin [17], coibamide-A [18], C-phycocyanin, and largazole [19, 20] have proved to be a potent anticancer agent to induce apoptosis in various cancer cell lines.”
Construction of Chalcogenated Methylene Chroman-3-ones via Palladium-Catalyzed Carbocyclization
Liu, M., Huang, J., Xu, H., & Dai, H. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c00341 · Cited by 2
HDAC inhibitors in cancer therapy
Ganesan, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816422-8.00002-7 · Cited by 3
Marine Microbes: Unexplored Therapeutic Bio-mine
Bisen, P. S. (2012) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000e112 · Cited by 2
“Some of potent compounds from cyanobacteria with anti-cancer activities which have garnered interest in recent years are largazole [16] and apratoxin [17].”
Screening Strategies for Drug Discovery and Target Identification
Al‐Awadhi, F. H., Salvador, L. A., & Luesch, H. (2015) · CRC Press eBooks · doi:10.1201/b19081-10 · Cited by 3
Self-citationDesign, structural derivation, and nematicidal activities of 1,2,3-benzotriazin-4-one derivatives
Xu, X., Chen, X., Wang, G., Zhang, J., Xiao, Y., Shen, H., Chang, Y., Li, W., Jia, H., Zhang, R., et al. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821035-2.00023-1 · Cited by 2
Molecular basis for depsipeptide HDAC inhibitor combinatorial biosynthesis
Passmore, M., Jian, X., Zhao, X., Santos, E. L. C. D. L., Roberts, D. M., Lewandowski, J. R., Jenner, M., Alkhalaf, L. M., & Challis, G. L. (2026) · Nature Communications · doi:10.1038/s41467-026-74383-4 · Cited by 2
Lu, Y., Wang, G., Zhou, M., Chen, T., & Fan, Z. (2026) · Marine Drugs · doi:10.3390/md24050170 · Cited by 2
“Largazole, from cyanobacteria Symploca sp., specifically binds to the catalytic domain of HDAC1 to inhibit histone deacetylase (HDAC) and induce HCT116 cell apoptosis at the nanomolar level [90].”
Brücksken, K. A., Lappe, L., Chen, Q.-Y., Luesch, H., Korsching, E., Reichstein, L., Marzi, A., Espinoza‐Sánchez, N. A., Habig, T., Fuentes‐Pananá, E. M., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1745079 · Cited by 1
“However, largazole is a prodrug and inevitably undergoes protein-assisted hydrolysis in human cells or cell culture, resulting in a largazole thiol and making the docking model unlikely to be accurate (Hong and Luesch, 2012; Liu et al., 2010).”
InfluentialSelf-citationWang, R., 刘南春, Wang, Y., Liu, S., & Gao, B. (2026) · Organic Letters · doi:10.1021/acs.orglett.6c02150 · Cited by 1
Peptide-based inhibitors of epigenetic proteins
Hintzen, J. C. J., & Mecinović, J. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.04.004 · Cited by 2
Vaske, Y. S. M., & Crews, P. (2013) · Wiley eBooks · doi:10.1002/9781118412893.ch1 · Cited by 1
Barghout, S. H. (2020) · TSpace (University of Toronto) · doi:10.13140/rg.2.2.10284.90246 · Cited by 1
The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes
Ganesan, A. (2012) · Wiley eBooks · doi:10.1002/9783527651085.ch5
Rewarding Incremental Innovation in Cancer Research
Bisen, P. S. (2013) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000e123
“Anti-cancer activity of compounds isolated from natural resources has been proven in various studies [5-13].”
Molecular Targets of Clinically Relevant Natural Products from Filamentous Marine Cyanobacteria
Tan, L. T. (2017) · Wiley eBooks · doi:10.1002/9783527805921.ch2
Wang, G., Wang, J., Yin, P., Xu, K., Wang, Y., Shi, F., Gao, J., & Fu, X. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27558
“The delay of tumor growth was shown in different mouse xenograft models for the alternative therapy of the SCD1 enzyme.(134) Bioactive lipid S1P, including the monoclonal antibody sphingomab, has been shown to effectively inhibit tumor growth, angiogenesis and metastasis of multiple cancer cells.”
Gaur, P. (2020) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.10556 · Cited by 2
Discovery of small-molecule inhibitors of Rad6 function and the Rad6-Rad18 interaction
Sharma, G. (2023) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.11653
Problems and Prospects of Applications of Cyanobacteria (Review)
Polyak, Y. M., & Сухаревич, В. И. (2023) · Inland Water Biology · doi:10.31857/s032096522301014x
(2025) · Studies in natural products chemistry · doi:10.1016/b978-0-443-23754-6.00006-9
Cyanobolites: Future Prospects in Therapeutics and Biological Innovation
Ojha, K. K., Dubey, S., Singh, A., Dixit, A. K., & Kumari, P. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1010149
Liu, Z., John, J., Johnson, N. A., Singh, P., Wang, Z., Sanchez, G. J., Simons, D., Wang, J. H., & Liu, X. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.21.700636 · Cited by 1
Cyanobacterial products with applications in health and industry
Barroso, C. P. M., Weiss, M. B., do Amaral, S. C., & Crnkovic, C. M. (2026) · Phytochemistry Reviews · doi:10.1007/s11101-026-10260-8
“Apratoxins—isolated from the cyanobacterium Lyngbya majuscule —are cyclo-depsipeptides with a unique structure, including a pentapeptide chain, a modified cysteine residue, and a highly functionalized polyketide chain (Hong and Luesch 2012).”
Editorial Introducing the Collection in Honor of Valerie J. Paul
Luesch, H., & Fenical, W. (2026) · Journal of Natural Products · doi:10.1021/acs.jnatprod.6c00688
Self-citationBindingDB Entry 50018413: Chemotherapeutics for
BindingDB (2024) · UC San Diego · doi:10.7270/q2r78kfr
BindingDB (2026) · UC San Diego · doi:10.7270/q2b85dzw
BindingDB Entry 50013364: Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
BindingDB (2022) · UC San Diego · doi:10.7270/q2f76h9k
BindingDB Entry 50008128: A fluorine scan on the Zn
BindingDB (2021) · UC San Diego · doi:10.7270/q2kk9g56
BindingDB Entry 50045291: Evaluation of class I HDAC isoform selectivity of largazole analogues.
BindingDB (2016) · UC San Diego · doi:10.7270/q25q4xrz
BindingDB (2019) · UC San Diego · doi:10.7270/q2m047mp
Metadata
- Authors
- Hong, J., & Luesch, H.
- Affiliations
- Duke University (US)
- University of Florida (US)
- Corresponding author
- Hong, Jiyong
- Luesch, Hendrik
- Venue
- Natural Product Reports
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2012
- Volume
- 29
- Issue
- 4
- Pages
- 449
- ISSN
- 0265-0568 (ISSN-L)
- 1460-4752
- PMC
- PMC4777309
- OpenAlex
- W2089288742
- Cited by
- 174
- References
- 47
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 7 · 2023: 14 · 2022: 16 · 2021: 13 · 2020: 16 · 2019: 13 · 2018: 14 · 2017: 6 · 2016: 8 · 2015: 11 · 2014: 20 · 2013: 12 · 2012: 6
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Natural Product Reports (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA138544)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- largazole, Symploca, cyclic depsipeptides, marine natural products, HDAC8, anticancer activity, osteogenic differentiation, structure-activity relationship, total synthesis, crystal structure, cancer therapy
- MeSH terms
- Cyanobacteria, Antineoplastic Agents, Biological Products, Humans, Marine Biology, Structure-Activity Relationship, Thiazoles, Molecular Structure, Depsipeptides, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.